Earnings summaries and quarterly performance for BeyondSpring.
Executive leadership at BeyondSpring.
Board of directors at BeyondSpring.
Research analysts who have asked questions during BeyondSpring earnings calls.
AH
Andy Hsieh
William Blair & Company
3 questions for BYSI
Also covers: ALT, CRDF, EXEL +8 more
Jason Gerberry
Bank of America Merrill Lynch
3 questions for BYSI
Also covers: ALKS, AMPH, ARWR +23 more
MR
Maurice Raycroft
Jefferies Financial Group
3 questions for BYSI
Also covers: ABEO, AFMD, ALNY +14 more
JB
Joel Beatty
Baird
2 questions for BYSI
Also covers: ACAD, ALKS, AMLX +11 more
Joseph Pantginis
H.C. Wainwright & Co.
2 questions for BYSI
Also covers: ARMP, BCDA, BLRX +15 more
CM
Chi Meng Fong
BofA Securities
1 question for BYSI
Also covers: BHC, EXEL, GUTS +2 more
JS
Josh Schimmer
Cantor Fitzgerald
1 question for BYSI
Also covers: BBIO, CRNX, KRYS +3 more
MR
Maury Raycroft
Jefferies
1 question for BYSI
Also covers: ABEO, ALNY, ARWR +11 more
Recent press releases and 8-K filings for BYSI.
BeyondSpring Reports Positive Phase 3 DUBLIN-3 Asian Subset Data for Plinabulin
BYSI
New Projects/Investments
- BeyondSpring announced positive results from the Asian subset (n=488) of its global Phase 3 DUBLIN-3 trial, evaluating Plinabulin plus docetaxel compared to docetaxel alone in second- or third-line EGFR wild-type non-small cell lung cancer (NSCLC).
- In this cohort, Plinabulin + docetaxel achieved a statistically significant improvement in overall survival (OS), with 10.8 months versus 8.8 months for docetaxel alone (HR 0.81, p=0.0426).
- The combination also demonstrated a marked reduction in docetaxel-induced grade 4 neutropenia (DP: 3.9% vs. D: 26.5%, p<0.0001), indicating a favorable tolerability profile.
- These findings strengthen the evidence for Plinabulin's potential as a new standard of care and support its advancement into a global Phase 3 confirmatory study.
Dec 12, 2025, 12:00 PM
BeyondSpring Announces Positive DUBLIN-3 Phase 3 Study Analyses and Plans for DUBLIN-4 Trial
BYSI
New Projects/Investments
- BeyondSpring announced new post-hoc analyses from its Phase 3 DUBLIN-3 Study, presented at NACLC 2025, demonstrating that Plinabulin plus docetaxel provides clinically meaningful benefits for EGFR wild-type non-squamous NSCLC patients who progressed after anti-PD-(L)1 immunotherapy.
- The combination showed improved median overall survival of 15.8 months compared to 11.7 months for docetaxel alone, and an objective response rate of 18.2% versus 8.0%.
- Plinabulin also demonstrated improved safety by significantly reducing docetaxel-induced grade 4 neutropenia (5.13% vs. 33.58%) and reduced the incidence of new brain metastasis to 4.32% compared to 7.83% for docetaxel alone.
- BeyondSpring plans to initiate a global Phase 3 DUBLIN-4 trial to serve as a confirmatory study, which, along with DUBLIN-3, is expected to support a future New Drug Application (NDA) submission.
Dec 11, 2025, 12:00 PM
BeyondSpring Inc. completes registered offering of ordinary shares
BYSI
- BeyondSpring Inc. entered into a Securities Purchase Agreement with Ray Beauty Group Limited on November 17, 2025.
- The company agreed to sell 800,000 ordinary shares at a purchase price of $2.50 per share.
- This transaction resulted in gross proceeds of $2.0 million for BeyondSpring Inc..
- The closing of the purchase and sale of the shares occurred on November 21, 2025.
- Ray Beauty Group Limited, as the investor, is subject to a 60-day lock-up period from the closing date, during which it cannot sell the shares without prior written consent.
Nov 21, 2025, 9:30 PM
BeyondSpring Inc. Reports Q3 2025 Financial Results and Corporate Updates
BYSI
Earnings
New Projects/Investments
Accounting Changes
- BeyondSpring Inc. reported a net loss attributable to the company of $1.540 million for Q3 2025, an improvement from a net loss of $2.132 million in Q3 2024.
- Cash and cash equivalents significantly increased to $12.5 million as of September 30, 2025, compared to $2.9 million as of December 2024.
- For continuing operations, Research and development expenses increased to $1.0 million in Q3 2025 from $0.6 million in Q3 2024, while General and administrative expenses decreased to $0.8 million from $1.7 million over the same period.
- SEED Therapeutics, in which BeyondSpring holds a 38% equity share, completed a $30 million Series A-3 financing and received U.S. FDA and China NMPA clearance for its lead RBM39 degrader program's Investigational New Drug (IND) application.
Nov 12, 2025, 12:00 PM
Quarterly earnings call transcripts for BeyondSpring.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more